Jeff Mirviss
@bsc_pi
Followers
2K
Following
6K
Media
460
Statuses
2K
Global President, PI, @bsc_vascular & @bsc_io at BSC. Passionate about the role of med tech in saving the lives and limbs of patients around the world.
Maple Grove, MN
Joined August 2009
RT @bsc_vascular: We’re excited to invite you to an upcoming VIVA webinar on September 3. Join us to explore the latest drug-elution data a….
0
2
0
0
1
0
76M w/ DM, HTN, CAD (post-PCI), ex-smoker & Rutherford 3 claudication. #RadialAccess angiography → severe calcified SFA.Tx: Orbital atherectomy + PTA w/ #RangerDCB 200cm.✅ Minimal residual stenosis.✅ Excellent runoff via dominant peroneal.Radial-first & device-enabled.
1
1
14
Big News! The 544th—and final—patient has been enrolled in #HIPEITHO, a landmark RCT comparing EKOS + anticoagulation vs. anticoagulation alone in intermediate-high risk #PE. Thank you to our investigators, @PERTConsortium & @UnimedizinMainz. Learn more:
1
13
47
FDA-approved. Clinically proven. Minimally invasive. #RangerDCB brings next-gen performance to #PAD procedures. Explore the new 200cm monorail platform: #DCB
0
2
6
Introducing #ENROUTE: The first and only transcarotid artery revascularization (#TCAR) system that reverses blood flow during stenting to protect the brain. See why physicians are making the switch: #OnePowerfulSwitch *Available in US only
0
1
7
RT @bsc_vascular: 🗓️ Join us at #NCVH2025 for a live case featuring an expert operator and panel who will discuss the application of #Range….
0
3
0
Excited to share that our dedicated investigators, @PERTConsortium & @UnimedizinMainz, have enrolled the 500th patient in #HIPEITHO! HI-PEITHO is the seminal global prospective multicenter RCT with primary endpoints that will be meaningful to all who manage patients with #PE
0
9
31
RT @bsc_vascular: Join us for an enlightening discussion as thought leaders spanning diverse medical specialties share the latest clinical….
0
1
0
Exciting news! Boston Scientific has officially closed the acquisition of @BoltIVL. We look forward to enhancing our PI portfolio and providing physicians and their patients with this advanced, innovative therapy for complex vascular diseases. #BoltIVL #ATK #BTK.
We have officially closed the acquisition of @BoltIVL. We look forward to advancing the intravascular lithotripsy (IVL) therapy developed by Bolt which will complement our cardiovascular portfolio by expanding treatment options for coronary and peripheral disease. $BSX
0
1
9
Presented at #ACC25 | #REALPEII: In a propensity-matched cohort of 1,465 PE patients treated with EKOS or FlowTriever, EKOS patients had lower rates of major bleeding within 7 days & readmissions within 30 days. Real-world evidence supports EKOS safety in #PE practice. #WhyWeEKOS
1
0
6
RT @VascularNews: New data from a large, real-world study support the use of drug-eluting devices to reduce amputations, readmissions, and….
vascularnews.com
New data from a large, real-world study support the use of drug-eluting devices in the treatment of peripheral arterial disease (PAD).
0
1
0
Presented at #LINC2025 | Ranger ISR analysis from the #ELEGANCERegistry showed high 84.2% K-M rate of freedom from CD-TLR rate at 12m across this diverse and complex 150-patient population, which included nearly 50% females and over 30% under-represented minorities. #RangerISR
0
2
10
Presented at #LINC2025 | TRUE-PTX data show that #PAD treatment with #paclitaxel #drugeluting devices may reduce the risk of amputation and readmission vs. treatment with non-drug devices. #TRUEPTX #EvidenceBasedMedicine
0
3
10
Big news! Upon close and regulatory approval, we look forward to providing physicians and their patients access to this emerging, high-growth therapy for treatment of complex cardiovascular diseases.
We’ve agreed to acquire @BoltIVL, developer of an intravascular lithotripsy (IVL) offering to treat coronary and peripheral disease, which will expand our cardiovascular portfolio with a complementary & differentiated calcium modification platform. $BSX
4
2
26
RT @SilkRoadMed: Continue following Silk Road Medical’s journey, now as a part of #BostonScientific, by following @bsc_pi and @bsc_vascular….
0
3
0
We’re excited to add TCAR technology to Boston Scientific’s portfolio. CAD is a rapidly growing therapy area affecting nearly half a million new patients annually in the US. As one company, we’re excited to bring this therapy to more patients. *Available only in US currently
2
2
14
RT @bsc_vascular: 🗓️Join us next week to discuss The "Usual" Intermediate-High Risk PE Case…And "What Else”.- The Usual: Standard PE case.-….
0
1
0
RT @SilkRoadMed: ROADSTER 3 30-day outcomes are in: TCAR delivers the lowest stroke rates in the first-ever independently adjudicated study….
0
2
0